A detailed history of Jacobs Levy Equity Management, Inc transactions in Xencor Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 207,622 shares of XNCR stock, worth $4.88 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
207,622
Previous 305,673 32.08%
Holding current value
$4.88 Million
Previous $5.79 Million 27.84%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.7 - $21.65 $1.54 Million - $2.12 Million
-98,051 Reduced 32.08%
207,622 $4.18 Million
Q2 2024

Aug 14, 2024

BUY
$18.21 - $24.5 $1.77 Million - $2.39 Million
97,446 Added 46.8%
305,673 $5.79 Million
Q1 2024

May 15, 2024

BUY
$18.65 - $26.52 $3.88 Million - $5.52 Million
208,227 New
208,227 $4.61 Million
Q4 2022

Feb 14, 2023

SELL
$24.79 - $30.86 $2.96 Million - $3.68 Million
-119,308 Reduced 64.81%
64,770 $1.69 Million
Q3 2022

Nov 15, 2022

SELL
$24.62 - $32.44 $3.12 Million - $4.11 Million
-126,729 Reduced 40.77%
184,078 $4.78 Million
Q2 2022

Aug 15, 2022

SELL
$19.74 - $29.01 $2.2 Million - $3.23 Million
-111,467 Reduced 26.4%
310,807 $8.51 Million
Q1 2022

May 16, 2022

BUY
$26.68 - $41.63 $11.3 Million - $17.6 Million
422,274 New
422,274 $11.3 Million
Q4 2021

Feb 14, 2022

SELL
$33.67 - $43.44 $1.24 Million - $1.6 Million
-36,780 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$30.65 - $35.68 $15,110 - $17,590
-493 Reduced 1.32%
36,780 $1.2 Million
Q2 2021

Aug 16, 2021

BUY
$34.33 - $44.68 $1.28 Million - $1.67 Million
37,273 New
37,273 $1.29 Million
Q3 2020

Nov 16, 2020

SELL
$30.09 - $43.02 $224,381 - $320,800
-7,457 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$27.76 - $33.42 $207,006 - $249,212
7,457 New
7,457 $242,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.4B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.